Bone marrow fibrosis

1. Navitoclax + ruxolitinib decreases bone marrow fibrosis in humans (JAKi-naïve myelofibrosis) (48% (13/27)).

   “BMF improved from baseline by ≥ 1 grade in 13/27 patients (48%) at any time on study.”

   Human trialJAKi-naïve myelofibrosisn = 27

   Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE)

   Hematological oncology·Mar 1, 2026

More on Navitoclax + ruxolitinib

1. Hydroxychloroquine decreases bone marrow fibrosis in mice (mice given multiple daily PTH injections).

   “In contrast, HCQ inhibited marrow fibrosis, but not osteoclast formation”

   Animalsmice given multiple daily PTH injectionsbone marrow

   Hydroxychloroquine and a low antiresorptive activity bisphosphonate conjugate prevent and reverse ovariectomy-induced bone loss in mice through dual antiresorptive and anabolic effects

   Bone research·Sep 5, 2024

More on Hydroxychloroquine